2023 New Drug Approvals: Part 1

News
Article

Take a look back at the novel drugs and therapeutics approved by the FDA in 2023,1 including treatments for Alzheimer disease, type 2 diabetes, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, and more.

References
1. Novel drug approvals for 2023. FDA. Reviewed November 28, 2023. Accessed November 28, 2023. https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023
2. FDA grants accelerated approval for Alzheimer’s disease treatment. News release. FDA. January 6, 2023. Accessed November 28, 2023. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment
3. TheracosBio announces FDA approval of Brenzavy (bexagliflozin) for the treatment of adults with type 2 diabetes. News release. TheracosBio. January 23, 2023. Accessed November 28, 2023. https://www.businesswire.com/news/home/20230123005126/en/TheracosBio-Announces-FDA-Approval-of-Brenzavvy%E2%84%A2-bexagliflozin-for-the-Treatment-of-Adults-with-Type-2-Diabetes
4. US FDA approves Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory mantle cell lymphoma after at least two lines fo systemic therapy, including a BTK inhibitor. News release. Eli Lilly. January 27, 2023. Accessed November 28, 2023. https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-jaypircatm-pirtobrutinib-first-and-only-non
5. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. FDA. January 27, 2023. Accessed November 28, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-elacestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast-cancer
6. FDA approves first oral treatment for anemia caused by chronic kidney disease for adults on dialysis. News release. FDA. February 1, 2023. Accessed November 28, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-anemia-caused-chronic-kidney-disease-adults-dialysis
7. FDA approves first enzyme replacement therapy for rare alpha-mannosidosis. FDA. February 17, 2023. Accessed November 28, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-enzyme-replacement-therapy-rare-alpha-mannosidosis
8. Travere Therapeutics announces FDA accelerated approval of Filsparitm (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy. News release. Travere Therapeutics. February 17, 2023. Accessed November 28, 2023. https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-fda-accelerated-approval
9. FDA approves first treatment for Friedreich’s ataxia. FDA. February 28, 2023. Accessed November 28, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-friedreichs-ataxia

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Image Credit: jokekung - stock.adobe.com
Image Credit: gamelover - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.